+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating an experimental drug called odronextamab combined with lenalidomide for adults with relapsed or refractory Follicular Lymphoma FL or Marginal Zone Lymphoma MZL, which are subtypes of Non-Hodgkins Lymphoma NHL. This Phase 3 study includes two parts Part 1 to assess safety and dosing of the combination, and Part 2 to compare its effectiveness and safety against the current standard treatment of rituximab plus lenalidomide. The combination of odronextamab and lenalidomide is a first-in-human treatment being explored in this trial. In Part 1, participants receive odronextamab with lenalidomide to evaluate safety and determine dosing. In Part 2, participants are randomly assigned to receive either odronextamab plus lenalidomide or rituximab plus lenalidomide followed by lenalidomide alone, allowing comparison between the new combination and standard care. Both treatment combinations are administered according to the study protocol. Participants will be monitored for side effects, treatment tolerability, and disease progression through scheduled assessments including imaging scans and laboratory tests. Researchers will measure drug levels in the blood, immune responses against odronextamab, and quality of life impacts using questionnaires. Safety monitoring continues for up to two years, while efficacy outcomes such as progression-free survival and response duration are followed for up to five years, with ongoing evaluations throughout the study period.

Age: 18Years +All GendersPhase 3
171 locations
C

Actively Recruiting

Researchers are evaluating an experimental drug called odronextamab in adults with previously untreated follicular lymphoma, a type of non-Hodgkin lymphoma. The study consists of two parts Part 1 focuses on assessing the safety and tolerability of odronextamab alone, while Part 2 compares odronextamab to rituximab combined with chemotherapy, which is the current standard treatment. The research also explores side effects, drug levels in the blood, immune responses against the drug, and effects on quality of life and daily activities. Participants in Part 1 receive only odronextamab. In Part 2, participants are randomly assigned to one of two groups one group receives odronextamab followed by maintenance treatment with the same drug, and the other group receives rituximab combined with chemotherapy followed by rituximab maintenance. Chemotherapy options include combinations of cyclophosphamide, doxorubicin, vincristine, prednisone, and bendamustine, administered as described in the study protocol. Throughout the study, participants undergo regular assessments including imaging scans to measure disease, blood tests to monitor drug levels and immune response, and evaluations of physical function and quality of life. Researchers track adverse events and treatment responses up to five years. Safety and effectiveness are closely monitored, with key outcomes measured at intervals up to 30 months and beyond. The total participation time varies depending on treatment and follow-up schedules.

Age: 18Years +All GendersPhase 3
190 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
E

Actively Recruiting

Researchers are evaluating the effects of respiratory muscle strengthening and diaphragmatic breathing exercises on pain levels, respiratory capacity, and sleep quality in adults aged 40 to 65 who experience shoulder pain and disability. The study compares two groups one receiving standard shoulder rehabilitation and the other receiving shoulder rehabilitation plus respiratory muscle and breathing exercises. The goal is to understand how these additional exercises impact shoulder pain and lung function. Participants are randomly assigned to either the experimental group, which receives respiratory muscle strengthening and diaphragmatic breathing exercises along with shoulder rehabilitation, or the control group, which receives shoulder rehabilitation alone. Spirometric measurements are taken before and after treatment in both groups to assess lung capacity changes. Alongside these interventions, the study evaluates pain levels, shoulder functionality, and sleep quality using various scales. During the study, participants undergo assessments of shoulder pain intensity, range of motion, pulmonary function, and sleep quality at baseline and three weeks after starting treatment. Spirometric tests are used to measure lung function, and questionnaires assess quality of life and sleep patterns. The main outcome is the change in the Shoulder Pain and Disability Index SPADI score. The total participation time covers the treatment period of three weeks with evaluations before and after this period.

Age: 40Years - 65YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are investigating how dual-task exercises, which combine physical and cognitive activities, delivered through telerehabilitation, affect balance, fall risk, cognitive functions, and sleep quality in older adults aged 65 to 74 years. Aging often leads to balance problems, higher fall risk, cognitive decline, and poor sleep, all impacting quality of life. This study explores whether remote dual-task training can improve these issues and support safer, more independent living for geriatric individuals. Participants are randomly assigned to one of two groups. The telerehabilitation group performs supervised dual-task exercises at home three times a week for four weeks via video calls with a physiotherapist. Each 60-minute session includes warm-up, combined motor and cognitive tasks targeting balance, posture, and mental functions, and cool-down. The control group receives an educational brochure covering posture, balance, sleep hygiene, and safe activity, with weekly phone calls to encourage adherence but no supervised sessions. Throughout the study, researchers assess participants balance, fall risk and fear, sleep quality, gait, functional mobility, mental state, and cognitive function at the start, after four weeks, and one month later. The physiotherapist monitors exercise form and safety during sessions. This approach aims to provide accessible, remote rehabilitation to improve physical and cognitive health in older adults while reducing barriers to care. The study runs from February to June 2026 with follow-up assessments after completion.

Age: 65Years - 74YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the effect of a model-based digital game on metabolic control, self-efficacy, and quality of life in children with type 1 diabetes T1DM. This randomized controlled trial includes children aged 8 to 13 diagnosed with T1DM who are followed in pediatric endocrinology clinics. The study aims to compare the digital game intervention to standard diabetes education to see if it improves these outcomes. The study involves two groups an experimental group that receives standard diabetes education followed by participation in a digital game based on the Information-Motivation-Behavioral Skills Model for diabetes management, and a control group that receives standard diabetes education and weekly visual slide sessions on nutrition, exercise, and medication use. The digital game participation lasts 9 weeks, with active monitoring and weekly reminders for incomplete stages. Both groups complete questionnaires and scales at the start and again at 12 and 15 weeks. After the study, the control group will also have access to the game. Participants will complete several questionnaires online, including the Quality of Life Scale for Children with Type 1 Diabetes and the Diabetes Management Self-Efficacy Scale. Routine blood tests such as HbA1c will be collected from hospital records at the start and after 12 weeks. Researchers will monitor participants engagement with the game or educational sessions and use these measures to assess outcomes. The total study duration includes baseline, 9 weeks of intervention, and follow-ups at 12 and 15 weeks.

Age: 8Years - 13YearsAll GendersPhase Not Applicable
2 locations
E

Actively Recruiting

Healthy Volunteer

The trial investigates the effect of controlled placental cord drainage on the third stage of labor and postpartum bleeding in women. It focuses on how this method, involving opening the clamp at the maternal end of the umbilical cord after cutting, may influence the duration of placental delivery, blood loss during the third stage and the second hour postpartum, and the risk of postpartum complications. The study addresses conflicting previous findings and aims to clarify whether placental cord drainage can safely shorten labor and reduce bleeding. Participants are randomly assigned to one of two groups an intervention group where the clamp on the maternal end of the umbilical cord is opened to allow placental blood to flow out until signs of placental separation appear, and a control group where the cord remains clamped until placental delivery. Both groups receive standard prophylactic treatment with synpitan, and the placenta is delivered using controlled cord traction. The intervention procedure lasts up to five minutes unless earlier placental separation signs are seen. During the study, researchers will monitor labor stages, measure blood loss using collection devices and scales, and record the duration of the third stage of labor. Vital signs, uterine tone, and postpartum complications are assessed, with follow-up including hemoglobin and hematocrit levels 24 hours after birth. Breastfeeding initiation and duration are also tracked. Monitoring continues for two hours postpartum to evaluate safety and outcomes related to blood loss and labor progress.

Age: 18Years - 35YearsFEMALEPhase Not Applicable
1 location